[go: up one dir, main page]

US20100324096A1 - Whitening Agent And Skin External Preparation - Google Patents

Whitening Agent And Skin External Preparation Download PDF

Info

Publication number
US20100324096A1
US20100324096A1 US12/866,472 US86647209A US2010324096A1 US 20100324096 A1 US20100324096 A1 US 20100324096A1 US 86647209 A US86647209 A US 86647209A US 2010324096 A1 US2010324096 A1 US 2010324096A1
Authority
US
United States
Prior art keywords
alkyl
whitening agent
formula
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/866,472
Other languages
English (en)
Inventor
Naoto Hanyu
Tomoko Saito
Takako Shibata
Kiyoshi Sato
Kimihiro Ogino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Amazon Technologies Inc
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40952264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100324096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Assigned to SHISEIDO COMPANY LTD. reassignment SHISEIDO COMPANY LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHIBATA, TAKAKO, SATO, KIYOSHI, OGINO, KIMIHIRO, HANYU, NAOTO, SAITO, TOMOKO
Assigned to AMAZON TECHNOLOGIES, INC. reassignment AMAZON TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROSS, PETER G.
Publication of US20100324096A1 publication Critical patent/US20100324096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a whitening agent and a skin external preparation, and particularly, to an active ingredient thereof.
  • Pigmentation in the skin such as pigmented spots and freckles are resulted from hyperpigmentation of melanin in the epidermis.
  • the hyperpigmentation is caused by acceleration of melanin production in epidermal melanocytes triggered by hormone abnormality or UV stimulation.
  • a whitening agent has been mixed into a skin external preparation with an aim to prevent and improve such abnormal melanin pigmentation.
  • ingredients that are mixed into a skin external preparation as a whitening agent there are vitamin C derivative, kojic acid, arbutin (4-hydroxyphenyl- ⁇ -D-glucopyranoside), Rucinol (4-n-butylresorcinol), ellagic acid, etc., which are known to have an inhibitory action on melanin production.
  • Patent Literature 1 describes a 2-aminothiazole compound having an antibacterial or bactericidal effect.
  • Patent Literature 2 describes a thiazole compound having a C17,20-lyase inhibitory effect.
  • Patent Literature 3 describes a thiazoline compound having a pest control effect on a harmful organism.
  • Patent Literature 1 Japanese Patent No. 3033178
  • Patent Literature 2 Japanese Unexamined Patent Publication No. 2005-532983
  • Patent Literature 3 Japanese Unexamined Patent Publication No. H6-25197
  • An object of the present invention is to provide a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound.
  • the present inventors conducted thorough research to solve the aforementioned problem. As a result, they have found that a specific thiazoline or oxazoline compound has an excellent inhibitory action on melanin production and also has extremely low cytotoxicity, thereby completing the present invention.
  • the whitening agent of the present invention comprises, as an active ingredient, a heterocyclic compound represented by the following formula (1) or a pharmacologically acceptable salt thereof:
  • A is C 1-6 alkyl, C 5-6 cycloalkyl, benzyl, benzylcarbonyl, benzoyl, or a group represented by formula (A1):
  • X 1 is CR 1 or N, wherein R 1 is H, C 1-6 alkyl, C 1-6 alkoxy, or OH;
  • X 2 is CR 2 or N, wherein R 2 is H, C 1-6 alkyl, C 1-6 alkoxy, or OH;
  • R 5 is C 1-6 alkyl, C 1-6 alkoxy, or OH
  • R 5 is an integer of 0 to 3, wherein when p is 2 or 3, R 5 may be the same or different;
  • Ra is H, C 1-6 alkyl, or C 2-6 alkenyl
  • Y is S or O
  • R 3 and R 4 are each independently H, C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 2-7 acyl, or the group (A1), or
  • one R 3 and one R 4 may together form a saturated or unsaturated 5- or 6-membered hydrocarbon ring condensed with the hetero ring to which R 3 and R 4 are bound, or
  • C(R 3 ) 2 or C(R 4 ) 2 may each independently be C ⁇ CH 2 ;
  • the present invention also provides the whitening agent, wherein Y is S.
  • the present invention also provides the whitening agent, wherein A is the group (A1).
  • the present invention also: provides the whitening agent, wherein is a single bond.
  • the present invention also provides the whitening agent, wherein is represented by formula (1-1):
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • the present invention also provides the whitening agent, wherein R 3 in the formula (1-1) is each independently H or C 1-6 alkyl.
  • the present invention also provides the whitening agent, wherein R 4 in the formula (1-1) is each independently H or C 1-6 alkyl, or C(R 4 ) 2 is C ⁇ CH 2 .
  • the present invention also, provides the whitening agent, wherein is represented by formula (1-2):
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • the present invention also provides the whitening agent, wherein R 3 and R 4 in the formula (1-2) are each independently H or C 1-6 alkyl.
  • the present invention also provides the whitening agent, wherein is a double bond.
  • the present invention also provides the whitening agent, wherein is represented by formula (1-3):
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • the present invention also provides the whitening agent, wherein is represented by formula (1-4):
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • the present invention also provides the whitening agent, wherein R 3 in the formula (1-3) or (1-4) is C 1-6 alkyl or the group (A1).
  • the present invention also provides the whitening agent, wherein R 4 in the formula (1-3) or (1-4) is H or C 1-6 alkyl.
  • the present invention also provides the whitening agent, wherein Ra is H.
  • the present invention also provides the whitening agent, wherein R 5 is C 1-6 alkyl.
  • the present invention also provides the whitening agent, wherein the active ingredient inhibits melanin production.
  • the present invention also, provides a skin external preparation or a cosmetic comprising any of the aforementioned heterocyclic compounds or a pharmacologically acceptable salt thereof.
  • the whitening agent of the present invention has an excellent inhibitory action on melanin production and also has extremely low cytotoxicity; therefore, it can be suitably mixed into a skin external preparation as a whitening agent.
  • the whitening agent of the present invention is represented by the following formula (1):
  • A is C 1-6 alkyl, C 5-6 cycloalkyl, benzyl, benzylcarbonyl, benzoyl, or a group represented by the following formula (A1):
  • X 1 is CR 1 or N, wherein R 1 is H, C 1-6 alkyl, C 1-6 alkoxy, or OH.
  • X 2 is CR 2 or N, wherein R 2 is H, C 1-6 alkyl, C 1-6 alkoxy, or OH.
  • an unsaturated 6-membered ring containing X 1 and X 2 is a benzene ring, a pyridine ring, or a pyrimidine ring.
  • R 5 is C 1-6 alkyl, C 1-6 alkoxy, or OH, and preferred examples thereof include C 1-6 alkyl.
  • R 5 is an integer of 0 to 3.
  • R 5 can be the same or different.
  • Ra is H, C 1-6 alkyl, or C 2-6 alkenyl, and preferred examples thereof include H.
  • an unsaturated 5-membered hetero ring containing Y is thiazole, thiazoline, oxazole, or oxazoline.
  • R 3 and R 4 can each independently be H, C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 2-7 acyl, or the aforementioned group (A1). Also, one R 3 and one R 4 may together form a saturated or unsaturated 5- or 6-membered hydrocarbon ring condensed with the hetero ring to which R 3 and R 4 are bound. Alternatively, C(R 3 ) 2 or C(R 4 ) 2 may each independently be C ⁇ CH 2 .
  • An example of the preferred compound represented by the formula (1) is a compound wherein Y ⁇ S.
  • Another example of the preferred compound represented by the formula (1) is a compound wherein A is the group (A1).
  • An example of the preferred compound wherein A is a group (A1) is a compound wherein is a single bond.
  • Preferred examples of such a compound include a compound represented by the following formula (1-1) or formula (1-2).
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • a preferred example of the compound represented by the formula (1-1) is a compound wherein R 3 is each independently H or C 1-6 alkyl.
  • Another preferred example of the compound represented by the formula (1-1) is a compound wherein R 4 is each independently H or C 1-6 alkyl, or a compound wherein C(R 4 ) 2 is C ⁇ CH 2 .
  • tho compound represented by the formula (1-2) is a compound wherein R 3 and R 4 are each independently H or C 1-6 alkyl.
  • a preferred example of the compound wherein A is the group (A1) is a compound wherein is a double bond.
  • Preferred examples of such a compound include a compound represented by the following formula (1-3) or formula (1-4).
  • R 3 , R 4 , R 5 , and Ra are as defined in the formula (1).
  • a preferred example of the compound represented by the formula (1-3) or formula (1-4) is a compound wherein R 3 is C 1-6 alkyl or the group (A1).
  • Another preferred example of the compound represented by the formula (1-3) or (1-4) is a compound wherein R 4 is H or C 1-6 alkyl.
  • the compound of the formula (1) can be synthesized by a known method or commercially available.
  • an appropriate protecting group is preferably used to allow the reaction to proceed efficiently.
  • the use of the protecting group can be carried out according to, for example, Protective Groups in Organic Synthesis by Theodora W. Greene and Peter G. M. Wuts.
  • a pure isomer or geometric isomer can be obtained by appropriately selecting a raw material and a reaction condition and performing a separation operation.
  • a pure isomer of the compound of the formula (1) as well as a mixture thereof are also included.
  • a compound wherein is a single bond and Ra ⁇ H in the formula (1) can be obtained by, for example, a reaction shown in the following scheme 1.
  • a reaction of an iso(thio)cyanate compound (2) with an ethanolamine compound (3) can be carried out, for example, in an appropriate solvent such as chloroform, while heating as needed.
  • a ring closure reaction of the (thio)urea compound (4) thus obtained can be carried out, for example, in the presence of an acid catalyst, while heating.
  • the above reaction can be carried out according to, for example, a method described in Japanese Unexamined Patent Publication No. S62-228089.
  • a compound wherein is a double bond and Ra ⁇ H in the formula (1) can be obtained by, for example, a reaction shown in the following scheme 2.
  • a reaction of a (thio)urea compound (5) with a ⁇ -haloketone compound (6) can be carried out in an appropriate solvent such as methanol, at room temperature or while heating, in the presence of a base such as triethylamine as needed.
  • This reaction can be carried out according to, for example, a method described in Japanese Unexamined Patent. Publication No. 2005-532983 and Japanese Patent No. 3023178.
  • the compound of the formula (1) can be converted into an acid-addition salt by an ordinary method as needed.
  • acid in the acid-addition salt include an inorganic salt such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and an organic acid such as acetic acid, propionic acid, citric acid, lactic acid, oxalic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, and methanesulfonic acid.
  • the compound of the formula (1) has an excellent inhibitory action on melanin production while exhibiting extremely low eytotoxieity. Therefore, the present compound is useful as a whitening agent and can be suitably mixed into various skin external preparations, particularly a skin external preparation intended to improve or prevent pigmented spots, freckles, skin dullness, and the like.
  • the compound amount is, in the total amount of the external agent, typically 0.0002% by mass or more, preferably 0.002% by mass or more. When it is too low, the effect cannot be fully exerted. Although no limitation is imposed on the upper limit, it is typically 30% by mass or less, preferably 20% by mass or less, and more preferably 5% by mass or less. When the compound is excessively mixed in, not only a remarkable effect reasonably expected from the increased amount may not be obtained but also formulation designing and usability may be affected.
  • the skin external preparation of the present invention can be produced by an ordinary method.
  • ingredients normally used in a skin external preparation such as a cosmetic product and a pharmaceutical product can be appropriately added to the skin external preparation of the present invention as needed as far as the effect of the present invention is not adversely affected.
  • an ingredient include oil, a humectant, an ultraviolet protective agent, an antioxidant, a metal ion chelating agent, a surfactant, a preservative, a moisturizer, a fragrance, water, an alcohol, a thickener, powder, a colorant, a crude drug, and various kinds of medicinal ingredients.
  • whitening agents such as vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, Rucinol, ellagic acid, tranexamic acid, and linoleic acid can be appropriately added.
  • the skin external preparation of the present invention is widely applicable to the fields of cosmetics, drugs, and quasi drugs. No particular limitation is imposed on the form of the skin external preparation as long as it is applicable to the skin. Any form such as a solution, an emulsion, a solid, a semi-solid, a powder, a powder dispersion, a water-oil-separated two-phase liquid, a water-oil-powder-separated three-phase liquid, an ointment, a gel, an aerosol, a mousse, and a stick can be applied.
  • the skin external preparation can be provided in any use form including a facial cosmetic such as a lotion, an emulsion, a cream, a pack, an essence, and a gel, and a makeup cosmetic such as a foundation, a makeup base, and a concealer.
  • a facial cosmetic such as a lotion, an emulsion, a cream, a pack, an essence, and a gel
  • a makeup cosmetic such as a foundation, a makeup base, and a concealer.
  • test for melanin production inhibition by the compounds of the formula (1) was conducted.
  • the test method is as follows.
  • the medium was removed by aspiration. Then 1 ml of EMEM medium containing 10% Alamar Blue solution was added, and a reaction was allowed to proceed at 37° C. After 30 minutes, 100 ⁇ L of the reaction mixture was transferred to a 96 well plate and fluorescence was measured at an excitation wavelength of 544 nm and a measurement wavelength of 590 nm. Using the value thus measured as a relative value of cell count, a ratio of the cell count (% cell count) of the test substance-added group to the test substance-absent group (group in which only the solvent was added) was calculated. The higher the % cell count, the lower the cytotoxicity. It was determined that a compound having the % cell count of 80% or more was non-cytotoxic, and that a compound having the % cell count of less than 80% was cytotoxic.
  • the cells after the cell proliferation test were washed with PBS three times, and then lysed by addition of 200 ⁇ L of 1M NaOH to measure an absorbance at 475 nm. Using the value thus measured as a relative value of the melanin amount, a ratio of the melanin amount (%) of the test substance-added group to the test substance-absent group (group in which only the solvent was added) was calculated. The lower the ratio of the melanin amount, the higher the melanin production-inhibitory effect.
  • the minimum final concentration of the test substance at which the ratio of the melanin amount (%) was 80% or less was provided as a minimum concentration for inhibition of melanin production (ppm).
  • the inhibitory effect on melanin production was evaluated according to the following criteria.
  • ⁇ the minimum concentration for inhibition of melanin production was 1 ppm or less.
  • ⁇ the minimum concentration for inhibition of melanin production was more than 1 ppm and 10 ppm or less.
  • N-(1-hydroxy-2-methylpropan-2-yl)-N′-phenylthiourea (80.1 g, 0.36 mol) was dissolved in 2,400 mL of 35% HCl, and the resulting mixture was stirred while heating at 90° C. for 1.5 hours. After cooling, the mixture was neutralized with NaOH and extracted with diethyl ether. The extract was washed with saturated brine and then anhydrous sodium sulfate was added. The organic phase was distilled off under reduced pressure and the residue was washed three times with hexane. The crystals thus obtained were dried under reduced pressure at room temperature, and then recrystallized from methanol twice to give 22.4 g of the title compound (yield 18%).
  • Formulation Examples of the skin external preparation of the present invention are shown.
  • one or more compounds of the present invention can be used.
  • Any of the skin external preparations shown in Formulation Examples below exerts a whitening effect because of the by the addition of the compound of the present invention.
  • Propylene glycol and caustic potash were dissolved in ion-exchanged water, and the resulting mixture was heated to and maintained at 70° C. (aqueous phase). Other components were mixed and melted by heat, and maintained at 70° C. (oil phase). The oil phase was gradually added to the aqueous phase, and after the complication of the addition, the resulting mixture was maintained at 70° C. for some time to allow a reaction to proceed. Subsequently, the mixture was homogeneously emulsified by a homomixer, and cooled to 30° C. while thoroughly stirring.
  • Propylene glycol and disodium ethylenediaminetetraacetate were dissolved in ion-exchanged water and the resulting mixture was maintained at 70° C. (aqueous phase). Other components were mixed and melted by heat, and maintained at 70° C. (oil phase). The oil phase was gradually added to the aqueous phase. The mixture was preliminarily emulsified at 70° C., homogeneously emulsified by a homomixer, and then cooled to 30° C. while thoroughly stirring.
  • Powder soap and borax were added to ion-exchanged water and dissolved with heat, and the resulting mixture was maintained at 70° C. (aqueous phase). Other components were mixed and melted by heat, and maintained at 70° C. (oil phase). While stirring, the oil phase was gradually added to the aqueous phase to allow a reaction to proceed. Upon completion of the reaction, the mixture was homogeneously emulsified by a homomixer, and then cooled to 30° C. while thoroughly stirring.
  • Carboxyvinyl polymer was dissolved in a small amount of ion-exchanged water (phase A).
  • Phase A Polyethylene glycol 1500 and triethanolamine were added to the remaining ion-exchanged water and dissolved with heat, and the resulting mixture was maintained at 70° C. (aqueous phase).
  • Other components were mixed and melted by heat, and maintained at 70° C. (oil phase).
  • the oil phase was added to the aqueous phase and preliminarily emulsified.
  • the resulting mixture was homogeneously emulsified by a homomixer and then cooled to 30° C. while thoroughly stirring.
  • Propylene glycol was added to ion-exchanged water, and the resulting mixture was heated and maintained at 70° C. (aqueous phase). Other components were mixed and melted by heat, and maintained at 70° C. (oil phase). While stirring the oil phase, the aqueous phase was gradually added to the oil phase. The resulting mixture was homogeneously emulsified by a homomixer and then cooled to 30° C. while thoroughly stirring.
  • Ethanol 10.0% by mass Dipropylene glycol 15.0 POE (50) oleyl ether 2.0 Carboxyvinyl polymer 1.0 Caustic soda 0.15 L-arginine 0.1 Compound of the present invention 5.0 Sodium 2-hydroxy-4-methoxybenzophenone sulfonate 0.05 Trisodium ethylenediaminetetraaceate dihydrate 0.05 Methylparaben 0.2 Fragrance q.s. Ion-exchanged water balance
  • Carboxyvinyl polymer was homogeneously dissolved in ion-exchanged water. Separately, the compound of the present invention and POE (50) oleyl ether were dissolved in 95% ethanol and then added to the aqueous phase. After addition of the remaining components, the resulting mixture was neutralized by caustic soda and L-arginine to increase the viscosity.
  • Phase A Ethyl alcohol (95%) 10.0% by mass POE (20) octyldodecanol 1.0 Pantothenyl ethyl ether 0.1 Compound of the present invention 2.0 Methylparaben 0.15
  • Phase B Potassium hydroxide 0.1
  • Phase C Glycerol 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 Purified water balance
  • Phase A and Phase C were homogeneously dissolved, and Phase A was added to Phase C to be solubilized. After addition of Phase B, the resulting mixture was packed in a container.
  • Phase A Dipropylene glycol 5.0% by mass POE (60) hydrogenated castor oil 5.0
  • Phase B Compound of the present invention 0.05 Olive oil 5.0 Tocopherol acetate 0.2 Ethylparaben 0.2 Fragrance 0.2
  • Phase C Sodium bisulfite 0.03 Polyvinyl alcohol 13.0 (saponification degree of 90 and polymerization degree of 2,000) Ethanol 7.0 Purified water balance
  • Phase A Phase A
  • Phase B Phase B
  • Phase C Phase C
  • Powdery components from talc to black iron oxide shown above were thoroughly mixed by a blender. To this mixture were added oily components from squalane to isocetyl octanoate shown above, the compound of the present invention, preservative, and fragrance. The resulting mixture was thoroughly kneaded, packed in a container, and then formed.
  • the aqueous phase was stirred with heat and then the powder part, which had been fully mixed and pulverized, was added.
  • the mixture was treated with a homomixer and then the oil phase, which had been mixed with heat, was added.
  • the mixture was treated with a homomixer and then fragrance was added while stirring. The mixture thus obtained was cooled to room temperature.
  • A Alcohol phase Ethanol 5.0% by mass POE oleyl ether 2.0 2-Ethylhexyl-p-dimethylaminobenzoate 0.18 Compound of the present invention 0.1 Fragrance 0.05 B: Aqueous phase 1,3-Butylene glycol 9.5 2-O-Ethyl ascorbic acid 0.5 Sodium pyrrolidonecarboxylate 0.5 Whey extract 5.0 Nicotinamide 0.3 Glycerol 5.0 Hydroxypropyl- ⁇ -cyclodextrin 1.0 Trisodium hydroxyethylethylenediamine triacetate 1.0 Lysine 0.05 Tranexamic acid 1.0 Purified water balance
  • Alcohol phase A was added to Aqueous phase B and solubilized to provide a lotion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US12/866,472 2008-02-08 2009-02-06 Whitening Agent And Skin External Preparation Abandoned US20100324096A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008029106 2008-02-08
JP2008-029106 2008-02-08
JP2008199606 2008-08-01
JP2008-199606 2008-08-01
PCT/JP2009/052079 WO2009099195A1 (ja) 2008-02-08 2009-02-06 美白剤及び皮膚外用剤

Publications (1)

Publication Number Publication Date
US20100324096A1 true US20100324096A1 (en) 2010-12-23

Family

ID=40952264

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/866,250 Active 2030-03-06 US8563552B2 (en) 2008-02-08 2009-02-06 Whitening agent and skin external preparation
US12/866,472 Abandoned US20100324096A1 (en) 2008-02-08 2009-02-06 Whitening Agent And Skin External Preparation
US12/866,460 Abandoned US20100316584A1 (en) 2008-02-08 2009-02-06 Whitening Agent And Skin External Preparation
US12/866,062 Active 2029-04-13 US8324234B2 (en) 2008-02-08 2009-02-06 Method for inhibiting melanin production and whitening skin with pyrimidylpyrazole compounds or pharmaceutically acceptable salts thereof
US13/367,577 Active US8211412B2 (en) 2008-02-08 2012-02-07 Method for skin whitening
US13/656,790 Active US8426435B2 (en) 2008-02-08 2012-10-22 Method for inhibiting melanin production and whitening skin with pyrimidlypyrazole compounds or pharmaceutically acceptable salts thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/866,250 Active 2030-03-06 US8563552B2 (en) 2008-02-08 2009-02-06 Whitening agent and skin external preparation

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/866,460 Abandoned US20100316584A1 (en) 2008-02-08 2009-02-06 Whitening Agent And Skin External Preparation
US12/866,062 Active 2029-04-13 US8324234B2 (en) 2008-02-08 2009-02-06 Method for inhibiting melanin production and whitening skin with pyrimidylpyrazole compounds or pharmaceutically acceptable salts thereof
US13/367,577 Active US8211412B2 (en) 2008-02-08 2012-02-07 Method for skin whitening
US13/656,790 Active US8426435B2 (en) 2008-02-08 2012-10-22 Method for inhibiting melanin production and whitening skin with pyrimidlypyrazole compounds or pharmaceutically acceptable salts thereof

Country Status (11)

Country Link
US (6) US8563552B2 (ja)
EP (5) EP2250999B1 (ja)
JP (4) JP4586108B2 (ja)
KR (4) KR101102640B1 (ja)
CN (4) CN101965176B (ja)
AU (1) AU2009211564B2 (ja)
BR (1) BRPI0908143B1 (ja)
ES (4) ES2582228T3 (ja)
RU (1) RU2434634C1 (ja)
TW (4) TWI348920B (ja)
WO (4) WO2009099192A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202860A2 (en) * 2010-03-10 2012-08-09 Galleon Pharmaceuticals, Inc. Analgesic Compounds, Compositions and Uses Thereof
US20130039870A1 (en) * 2010-03-23 2013-02-14 Beiersdorf Ag Cosmetic Or Dermatological Preparations With A Content Of One Or More Thiazole Derivates
US9533963B2 (en) 2011-09-23 2017-01-03 Beiersdorf Ag Alkylamidothiazoles, cosmetic or dermatological preparations containing said alkylamidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
US9610234B2 (en) 2013-03-11 2017-04-04 Beiersdorf Ag Combinations of alkylamidothiazoles and preservatives
KR20240116232A (ko) * 2023-01-20 2024-07-29 대전대학교 산학협력단 1,3-디옥틸옥시벤젠을 유효성분으로 포함하는 피부미백제

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563552B2 (en) * 2008-02-08 2013-10-22 Shiseido Company Ltd. Whitening agent and skin external preparation
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
JP5164179B2 (ja) * 2009-12-28 2013-03-13 株式会社 資生堂 液状化粧料
WO2011086955A1 (ja) 2010-01-18 2011-07-21 株式会社 資生堂 ピリミジニルピラゾール化合物の製造方法
JP5693862B2 (ja) * 2010-02-24 2015-04-01 株式会社 資生堂 美白日焼け止め化粧料
JP2013523721A (ja) * 2010-03-31 2013-06-17 株式會社アモーレパシフィック メラニン色素生成抑制剤及びこれを含有する化粧料組成物
WO2012124436A1 (ja) * 2011-03-17 2012-09-20 株式会社 資生堂 皮膚化粧料
TWI566772B (zh) * 2011-04-12 2017-01-21 資生堂股份有限公司 美白劑及黑色素生成抑制劑
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
DE102011083283A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen
WO2013172525A1 (ko) * 2012-05-16 2013-11-21 주식회사 코씨드바이오팜 어류 안구의 파쇄물 또는 추출물을 함유하는 화장료, 약학 및 식품 조성물
DE102013204088A1 (de) * 2013-03-11 2014-09-11 Beiersdorf Ag Wirkstoffkombinationen aus Alkylamidothiazolen und einen oder mehreren kosmetisch oder dermatologisch relevanten Duftstoffen
DE102013204070A1 (de) 2013-03-11 2014-09-11 Beiersdorf Ag Verwendung kosmetisch oder dermatologisch unbedenklicher substituierter Michael-Akzeptoren zur Verhinderung, Verminderung oder Prophylaxe der Tyrosinaseaktivität der menschlichen Haut und/oder deren Aufhellung
DE102013204097A1 (de) 2013-03-11 2014-10-30 Beiersdorf Ag Wirkstoffkombinationen aus Alkylamidothiazolen und einer oder mehreren kosmetisch oder dermatologisch unbedenklichen UV-Filtersubstanzen
DE102013204110A1 (de) 2013-03-11 2014-09-25 Beiersdorf Ag Wirkstoffkombinationen aus Alkylamidothiazolen und einem oder mehreren Cyclodextrinen
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN103822976B (zh) * 2013-10-15 2015-05-27 辽宁省食品药品检验所 一种测定化妆品中4-甲氧基水杨酸钾的方法
SG10201804347QA (en) 2013-11-29 2018-06-28 Mtg Co Ltd Aqueous skin care agent
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
DE102014223570A1 (de) * 2014-11-19 2016-05-19 Beiersdorf Ag Zubereitungen mit einem Gehalt an Ascorbinsäure, Ubidecarenon und Phosphationen zur verbesserten Hautkonturierung bzw. gegen Cellulite
CN107635981B (zh) * 2015-02-17 2020-08-04 中国科学院广州生物医药与健康研究院 用于诱导白色脂肪组织褐变的化合物和方法
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US10646487B2 (en) 2016-07-14 2020-05-12 Showa Denko K.K. Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant
JP6997197B2 (ja) 2017-01-23 2022-01-17 カデント セラピューティクス，インコーポレーテッド カリウムチャネルモジュレーター
JP7731064B2 (ja) 2017-04-19 2025-08-29 御木本製薬株式会社 トラネキサム酸類配合製剤
EP3675809B1 (de) 2017-08-31 2023-09-27 Basf Se Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
CN108929271B (zh) * 2018-06-29 2021-08-31 中国药科大学 酪氨酸酶抑制剂及其制备方法与用途
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
CN109758379A (zh) * 2019-03-20 2019-05-17 广州纳丽生物科技有限公司 一种复方凝血酸组合物及其制备方法、产品
JP2021100925A (ja) * 2019-10-31 2021-07-08 共栄化学工業株式会社 皮膚外用剤
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
JP2021161112A (ja) * 2020-03-31 2021-10-11 株式会社コーセー 組成物
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CN112675076A (zh) * 2021-01-04 2021-04-20 上海新高姿化妆品有限公司 一种提亮肤色的化妆品组合物及其制备方法与应用
WO2023002873A1 (ja) * 2021-07-21 2023-01-26 株式会社資生堂 皮膚浸透用化粧料、及び皮膚浸透用化粧料の製造方法
DE102022209937A1 (de) 2022-09-21 2024-03-21 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und einem oder mehreren Biopolymeren
CN115991698B (zh) * 2022-11-03 2024-03-29 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用
JPWO2024135395A1 (ja) * 2022-12-22 2024-06-27
JPWO2024142837A1 (ja) * 2022-12-26 2024-07-04
DE102023210919A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und Gamma-Undecalacton
DE102023210917A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und Isobutylchinolin
DE102023210909A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und einem oder mehreren aliphatischen verzweigten oder unverzweigten Aldehyden
DE102023210906A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und Indol
DE102023210907A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und delta-Decalacton
DE102023210912A1 (de) 2023-11-03 2025-05-08 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und Ethylmaltol
DE102023211235A1 (de) 2023-11-13 2025-05-15 Beiersdorf Aktiengesellschaft Wirkstoffkombinationen aus Alkylamidothiazolen und Ölkomponenten
WO2025110033A1 (ja) * 2023-11-24 2025-05-30 株式会社 資生堂 化粧料
WO2025115637A1 (ja) * 2023-11-28 2025-06-05 株式会社 資生堂 化粧料
WO2025134805A1 (ja) * 2023-12-22 2025-06-26 株式会社資生堂 化粧料
WO2025142473A1 (ja) * 2023-12-25 2025-07-03 株式会社資生堂 化粧料

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332627A (en) * 1990-10-30 1994-07-26 Sony Corporation Field emission type emitter and a method of manufacturing thereof
US5369116A (en) * 1992-07-03 1994-11-29 Ube Industries, Ltd. Polyfluorinated thiazoline derivative and chemical for controlling noxious organisms containing the same
US20040198773A1 (en) * 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
US20040209924A1 (en) * 2001-09-26 2004-10-21 Barry Hart Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
US20040236110A1 (en) * 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) * 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
US20070042997A1 (en) * 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
US20090274637A1 (en) * 2005-04-27 2009-11-05 Philippe Msika Depigmenting or Brigthening Cosmetic Composition at Least One Oxazolin as an Active Ingredient

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54117029A (en) * 1978-02-28 1979-09-11 Hokko Chem Ind Co Ltd Agricultural and horticultural microbicide
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
JPS62404A (ja) 1985-06-25 1987-01-06 Takeda Chem Ind Ltd 農業用殺菌剤
EP0234104B1 (en) * 1985-12-03 1990-10-24 Sumitomo Chemical Company, Limited Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient
ZA868951B (en) * 1985-12-07 1987-08-26 Shionogi & Company Limited Organophosphorus compounds having pesticidal activity
EP0264883A3 (en) * 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
EP0278610A3 (en) * 1987-02-13 1990-03-14 Sumitomo Chemical Company, Limited Novel pyridinyl-s-triazine derivatives, method for production thereof and a fungicide containing them as the active ingredient
JP3033178B2 (ja) 1990-10-30 2000-04-17 ソニー株式会社 電界放出型エミッタ
JP2997071B2 (ja) 1991-01-11 2000-01-11 和彦 石井 痔疾治療剤
JP2680771B2 (ja) 1992-06-17 1997-11-19 大建工業株式会社 無機質下地板
JP3154834B2 (ja) * 1992-10-23 2001-04-09 第一製薬株式会社 チロシナーゼ阻害剤
JP3023178B2 (ja) 1994-11-29 2000-03-21 久光製薬株式会社 ２−アミノチアゾール誘導体およびその塩類からなる抗菌剤または殺菌剤
JPH08208620A (ja) 1995-02-03 1996-08-13 Takeda Chem Ind Ltd アミノピラゾール誘導体、その製造法および用途
JPH08231520A (ja) * 1995-02-28 1996-09-10 Showa Sangyo Co Ltd チロシナーゼ阻害剤
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
FR2768618B1 (fr) * 1997-09-23 1999-10-22 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
FR2769221B1 (fr) * 1997-10-03 2000-01-14 Oreal Composition oxydante et utilisations pour la teinture, pour la deformation permanente ou pour la decoloration des fibres keratiniques
DE10008907A1 (de) * 2000-02-25 2001-08-30 Haarmann & Reimer Gmbh Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole
US20020016358A1 (en) * 2000-04-19 2002-02-07 Nof Corporation Cosmetic composition
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
WO2003027095A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
EP1437348A1 (fr) * 2003-01-13 2004-07-14 L'oreal Dérivés de de la 6-méthyl-pyrimidine-2,4-diamine, procédé de synthèse, compositions les comprenant et utilisations comme agents neutralisants basiques
EP1594438B1 (fr) * 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
DE602004016992D1 (de) 2003-05-02 2008-11-20 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
EP1863796A1 (en) 2005-03-22 2007-12-12 NeuroSearch A/S Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
AU2006257647A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
WO2006133876A1 (en) 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Use of pyrimidine derivatives for cosmetic purposes
KR100716891B1 (ko) * 2005-11-01 2007-05-09 (주)아모레퍼시픽 피리딘 티아졸 카복사마이드 유도체, 이의 제조방법 및이를 함유하는 피부 미백용 조성물
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US8563552B2 (en) * 2008-02-08 2013-10-22 Shiseido Company Ltd. Whitening agent and skin external preparation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332627A (en) * 1990-10-30 1994-07-26 Sony Corporation Field emission type emitter and a method of manufacturing thereof
US5369116A (en) * 1992-07-03 1994-11-29 Ube Industries, Ltd. Polyfluorinated thiazoline derivative and chemical for controlling noxious organisms containing the same
US20040198773A1 (en) * 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
US20040209924A1 (en) * 2001-09-26 2004-10-21 Barry Hart Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
US20040236110A1 (en) * 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) * 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
US20070042997A1 (en) * 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
US20090274637A1 (en) * 2005-04-27 2009-11-05 Philippe Msika Depigmenting or Brigthening Cosmetic Composition at Least One Oxazolin as an Active Ingredient

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bilodeau et al, Bioorg. Med. Chem. Lett., 2004, 14(11), 2941-2945. *
Gonzalez et al, Heterocycles, 1990, 30(1), 463-469. *
Hirashima et al J. Insect Sci, 2003, 3(4), 1-9. *
Hunter et al, JCS, 1959, 784-788. *
Shikhaliev et al , Russian Journal of General Chemistry, 2005, 75(2), 294-297. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202860A2 (en) * 2010-03-10 2012-08-09 Galleon Pharmaceuticals, Inc. Analgesic Compounds, Compositions and Uses Thereof
US9102636B2 (en) * 2010-03-10 2015-08-11 Galleon Pharmaceuticals, Inc. Analgesic compounds, compositions, and uses thereof
US20130039870A1 (en) * 2010-03-23 2013-02-14 Beiersdorf Ag Cosmetic Or Dermatological Preparations With A Content Of One Or More Thiazole Derivates
US8920785B2 (en) * 2010-03-23 2014-12-30 Beiersdorf Ag Cosmetic or dermatological preparations with a content of one or more thiazole derivates
US9533963B2 (en) 2011-09-23 2017-01-03 Beiersdorf Ag Alkylamidothiazoles, cosmetic or dermatological preparations containing said alkylamidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
US9610234B2 (en) 2013-03-11 2017-04-04 Beiersdorf Ag Combinations of alkylamidothiazoles and preservatives
KR20240116232A (ko) * 2023-01-20 2024-07-29 대전대학교 산학협력단 1,3-디옥틸옥시벤젠을 유효성분으로 포함하는 피부미백제
KR102852940B1 (ko) 2023-01-20 2025-08-29 대전대학교 산학협력단 1,3-디옥틸옥시벤젠을 유효성분으로 포함하는 피부 미백용 조성물

Also Published As

Publication number Publication date
EP2250999A4 (en) 2011-05-11
TW200938226A (en) 2009-09-16
KR20100111293A (ko) 2010-10-14
TW200938229A (en) 2009-09-16
CN101965177A (zh) 2011-02-02
ES2582176T3 (es) 2016-09-09
ES2582227T3 (es) 2016-09-09
TW200938227A (en) 2009-09-16
US8426435B2 (en) 2013-04-23
AU2009211564A1 (en) 2009-08-13
RU2434634C1 (ru) 2011-11-27
HK1149488A1 (en) 2011-10-07
EP2251001A4 (en) 2013-01-09
TWI353246B (en) 2011-12-01
EP2250998A4 (en) 2011-05-11
CN101938988A (zh) 2011-01-05
HK1150757A1 (en) 2012-01-13
CN101965176A (zh) 2011-02-02
ES2582228T3 (es) 2016-09-09
CN101938989B (zh) 2012-07-11
BRPI0908143A2 (pt) 2015-08-11
JPWO2009099194A1 (ja) 2011-05-26
TW200938228A (en) 2009-09-16
US20120134944A1 (en) 2012-05-31
ES2655305T3 (es) 2018-02-19
US20100316584A1 (en) 2010-12-16
US8324234B2 (en) 2012-12-04
WO2009099194A1 (ja) 2009-08-13
WO2009099193A1 (ja) 2009-08-13
BRPI0908143B1 (pt) 2016-12-20
WO2009099195A1 (ja) 2009-08-13
CN101938988B (zh) 2013-06-19
EP3067038B1 (en) 2017-10-11
JPWO2009099193A1 (ja) 2011-05-26
TWI337876B (ja) 2011-03-01
HK1149487A1 (en) 2011-10-07
EP3067038A1 (en) 2016-09-14
TWI381856B (zh) 2013-01-11
US8211412B2 (en) 2012-07-03
EP2250998A1 (en) 2010-11-17
EP2250998B1 (en) 2016-04-13
US20130045173A1 (en) 2013-02-21
JP4592820B2 (ja) 2010-12-08
TWI348920B (en) 2011-09-21
KR101102640B1 (ko) 2012-01-04
KR101039220B1 (ko) 2011-06-03
EP2251001A1 (en) 2010-11-17
EP2250999A1 (en) 2010-11-17
KR101047242B1 (ko) 2011-07-06
KR101037515B1 (ko) 2011-05-26
EP2251000A4 (en) 2011-05-11
KR20100121618A (ko) 2010-11-18
US8563552B2 (en) 2013-10-22
JP4613248B2 (ja) 2011-01-12
EP2251000B1 (en) 2016-04-13
JPWO2009099195A1 (ja) 2011-05-26
WO2009099192A1 (ja) 2009-08-13
US20110003838A1 (en) 2011-01-06
KR20100121617A (ko) 2010-11-18
EP2250999B1 (en) 2016-04-13
CN101965176B (zh) 2012-06-20
CN101938989A (zh) 2011-01-05
KR20100120150A (ko) 2010-11-12
JP4665052B2 (ja) 2011-04-06
JPWO2009099192A1 (ja) 2011-05-26
EP2251000A1 (en) 2010-11-17
JP4586108B2 (ja) 2010-11-24
AU2009211564B2 (en) 2013-08-29
US20110003817A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
US20100324096A1 (en) Whitening Agent And Skin External Preparation
AU2013242832B2 (en) Skin whitening agent and external preparation for the skin
HK1150538A (en) Skin whitening agent and external preparation for the skin
HK1149488B (en) Skin whitening agent and external preparation for the skin

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHISEIDO COMPANY LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANYU, NAOTO;SAITO, TOMOKO;SHIBATA, TAKAKO;AND OTHERS;SIGNING DATES FROM 20100707 TO 20100720;REEL/FRAME:024799/0394

AS Assignment

Owner name: AMAZON TECHNOLOGIES, INC., NEVADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROSS, PETER G.;REEL/FRAME:025242/0553

Effective date: 20101026

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION